登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer
ClinicalTrials.gov 上登记的一项乳腺癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06313086,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
3.Patients with unresectable locally advanced or metastatic breast cancer confirmed by histology;
入选标准第 3 条
5.Previously received regimens containing trastuzumab and taxanes at the advanced stage of disease.
入选标准第 5 条
1. Patients who have previously received tubulin inhibitor-loaded HER2 ADC therapy
排除标准第 1 条
5. Has not recovered from adverse reactions caused by previous anti-tumor treatments to ≤ Grade 1 or baseline (refer to NCI CTCAE 5.0);
排除标准第 5 条
6. NCI-CTCAE 5.0 ≥Grade 2 peripheral nephropathy occurred during previous systemic anti-tumor treatment;
排除标准第 6 条
7. Received immunotherapy, macromolecular targeted therapy or other anti-tumor biological therapy within 4 weeks before randomization, or received endocrine therapy, cytotoxic drug chemotherapy and small molecular targeted drug therapy within 2 weeks before randomization, or received traditional Chinese medicine preparations with anti-tumor indications within 2 weeks before randomization .
排除标准第 7 条
6.The Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2;
入选标准第 6 条
2. History of any other malignant tumors within three years
排除标准第 2 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:化验:血常规、肝肾功能;影像与可测量病灶;怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06313086,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
1.Voluntarily agree to participate in the study and sign the informed consent; 2.Age≥18 years old; 3.Patients with unresectable locally advanced or metastatic breast cancer confirmed by histology; 4.Confirmed to be HER2 positive (HER2-positive is defined as IHC 3+ or IHC 2+ with ISH positive); 5.Previously received regimens containing trastuzumab and taxanes at the advanced stage of disease. 6.The Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2; 7.Patients with adequate organ functions; 8.Life expectancy ≥ 3 months; 9.Female and male patients of childbearing age must agree to take adequate contraceptive measures during the entire study period.排除标准:Exclusion Criteria:
1. Patients who have previously received tubulin inhibitor-loaded HER2 ADC therapy 2. History of any other malignant tumors within three years 3. With uncontrollable serous effusion within 14 days before randomization, which required frequent drainage or medical intervention. 4. Known contraindication to the study drugs; 5. Has not recovered from adverse reactions caused by previous anti-tumor treatments to ≤ Grade 1 or baseline (refer to NCI CTCAE 5.0); 6. NCI-CTCAE 5.0 ≥Grade 2 peripheral nephropathy occurred during previous systemic anti-tumor treatment; 7. Received immunotherapy, macromolecular targeted therapy or other anti-tumor biological therapy within 4 weeks before randomization, or received endocrine therapy, cytotoxic drug chemotherapy and small molecular targeted drug therapy within 2 weeks before randomization, or received traditional Chinese medicine preparations with anti-tumor indications within 2 weeks before randomization . 8. Major organ surgery (excluding needle biopsy) within 28 days before randomization; 9. Untreated (including baseline findings) or unstable cerebral parenchymal metastasis, spinal cord metastasis or compression, and cancerous meningitis. 10.The cumulative amount of previous exposure to anthracyclines has reached the dosage; 11.History of LVEF < 40%, symptomatic congestive heart failure (CHF), 12.Serious or uncontrolled cardiovascular disease; 13.History of (non-infectious) interstitial lung disease/pneumonitis requiring steroid hormone therapy; 14.Patients who currently have ocular diseases that require medication or surgical intervention; or unwilling to stop wearing contact lenses during the study. 15.Active infections requiring intravenous antibiotics, antivirals, or antifungals within 14 days before randomization; 16.There are other circumstances that may interfere with the subject's participation in the study procedures or do not meet the subject's maximum benefit from participating in the study or affect the study results.
引自 ClinicalTrials.gov, NCT06313086, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06313086,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。